Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBT Margin (2016 - 2025)

Historic EBT Margin for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to 55.73%.

  • Ironwood Pharmaceuticals' EBT Margin rose 367600.0% to 55.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.66%, marking a year-over-year increase of 986100.0%. This contributed to the annual value of 47.55% for FY2024, which is 3128500.0% up from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' EBT Margin is 55.73%, which was up 367600.0% from 44.37% recorded in Q2 2025.
  • Ironwood Pharmaceuticals' EBT Margin's 5-year high stood at 139.03% during Q4 2024, with a 5-year trough of 1002.24% in Q2 2023.
  • Moreover, its 5-year median value for EBT Margin was 45.43% (2021), whereas its average is 23.24%.
  • In the last 5 years, Ironwood Pharmaceuticals' EBT Margin plummeted by -10575500bps in 2023 and then soared by 10222300bps in 2024.
  • Ironwood Pharmaceuticals' EBT Margin (Quarter) stood at 39.49% in 2021, then surged by 71bps to 67.41% in 2022, then plummeted by -348bps to 166.88% in 2023, then soared by 183bps to 139.03% in 2024, then crashed by -60bps to 55.73% in 2025.
  • Its EBT Margin stands at 55.73% for Q3 2025, versus 44.37% for Q2 2025 and 88.16% for Q1 2025.